CHAMPS (the Controlled High Risk Avonex Multiple Sclerosis trial) Update

Abstract

The optic neuritis treatment trial (ONTI) confirmed the strong association between optic neuritis and multiple sclerosis by identifying those at highest risk for the development of recurrent demyelinating events. For instance, those patients with three or more white matter lesions had a 51% chance of developing multiple sclerosis over the subsequent five years.3 In contrast, those with normal MR scans only had a 16% chance of developing clinically definite MS over the same time period.CLchamp

    Similar works